Salute e Benessere

MOBILion Systems to Present Transformative Advances in Proteomics Sensitivity…

As proteomics research increasingly emphasizes PTMs and proteoforms as critical indicators in drug development and clinical diagnostics, technologies that enhance detection depth and confidence are reshaping how scientists interrogate biological complexity. MOBILion's PAMAF technology enables near-100% ion utilization and delivers industry-leading spectral generation rates exceeding 500Hz. This performance advancement can only be achieved via MOBILion's high-speed HRIM separation and reduces the…
PR Newswire
04/11/2025

Novo Nordisk submits updated proposal to acquire Metsera, Inc.

Bagsværd, Denmark, 4 November 2025– On 30 October 2025, Novo Nordisk announced the submission of an unsolicited proposal to acquire Metsera, Inc. (Metsera) 1.Today, Novo Nordisk confirms that it has submitted an updated, unsolicited proposal to acquire Metsera. The updated proposal has been declared superior by Metsera’s board of directors.The acquisition of Metsera, including its early and development-stage incretin and non-incretin analogue peptide programmes, would provide Novo...
Nasdaq GlobeNewswire
04/11/2025

ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT OCTOBER 2025

Accumulated revenue for January – October 2025 increased by 55% to SEK 2,629.7 (1,693.2) million. Accumulated revenue for January –October 2025increased by 55% to SEK 2,629.7 (1,693.2) million. Revenues were distributed as follows: Countries in regions: -The Nordics:Denmark, Faroe Island,Finland,Iceland,Norway,Sweden - Central Europe :Austria,Germany,Switzerland - East Europe :Czech Republic,Slovakia,Hungary,Poland,Romania -South...
PR Newswire
04/11/2025

Trading by management and close relations of management

In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. The released shares relate to the 2022 legacy Chr. Hansen matching shares program and the legacy Chr. Hansen 2023 restricted stock units (RSU) program...
Nasdaq GlobeNewswire
04/11/2025

Renowned Pharma and Biotech Development Leader, Dr. Andreas Wallnöfer, is named…

(“ Optigo ”), an ophthalmology company pioneering next-gen treatments for retinal diseases, today announced that Dr. Andreas Wallnöfer is joining its Board of Directors as the company advances its lead program to IND-enabling studies.“Andreas is exactly the strategic leader and industry veteran we were looking for,” said Dr. Henning Afflerbach, Chair of the Board of Optigo. “His singular blend of operational experience — from bench to boardroom — and his track record of guiding programs...
Nasdaq GlobeNewswire
04/11/2025

Metabolon Powers Largest-Ever Veteran Metabolomics Study with Global Discovery…

Launched by the U.S. Department of Veterans Affairs in 2011, the Million Veteran Program is a landmark initiative exploring how genetics, lifestyle, military service, and environmental exposures affect health. With over one million enrolled veterans as of November 2023, MVP collects biospecimens, health surveys, and electronic medical records to power a secure, diverse, and expansive multiomics database. Veteran-focused research provides a window into the health effects of extreme stress…
PR Newswire
04/11/2025

Coloplast Finance B.V. - Annual Report, 2024/25

Hereby please find the Annual Report 2024/25 for the group of Coloplast A/S. Attachment 11_2025_Annual_Report_2024-25
Nasdaq GlobeNewswire
04/11/2025

Boehringer Ingelheim and CDR-Life Expand Collaboration Efforts with Global…

New deal builds on the success of a longstanding partnership in retinal health and the potential of CDR-Life’s unique antibody fragment-based platform Agreement provides potential for up to approx. USD 570 million in total payments including approx. USD 48 million in upfront and near-term payments, plus tiered royalties Ingelheim, Germany and Zurich , Switzerland – November4 , 2025– Boehringer Ingelheim and CDR-Life, Inc. today announced a new global licensing...
Nasdaq GlobeNewswire
04/11/2025

AmacaThera Signs Exclusive Global Licensing Agreement with Pacira BioSciences…

Under the terms of the agreement, AmacaThera will receive US$5 million upfront and up to US$225 million in future development- and sales-based milestone payments and a tiered royalty on future net sales. The companies will collaborate on clinical development, with AmacaThera leading select clinical studies. Pacira will fund clinical development of AMT-143 through commercial launch. Pacira and AmacaThera expect to initiate a Phase 2 trial in 2026, after which Pacira will assume full…
PR Newswire
04/11/2025

Zelluna ASA: Notice of extraordinary general meeting on 25 November 2025

The Company's board of directors (the "Board") hereby calls for an extraordinary general meeting on 25 November 2025 at 09:00 CET (the "EGM") to resolve upon proposals by the Board to issue the new shares in tranche 2 of the private placement and to authorize the Board to issue new shares in a potential subsequent repair offering, as further described in the attached EGM notice.The EGM will be held electronically. For participation, please log in…
Nasdaq GlobeNewswire
04/11/2025

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate…

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate UpdateSharpened investment focus on high-value assets, including three Phase 2 active immunotherapy programs and small molecule programs targeting NLRP3, Tau and a-synCash resources of CHF 108.5 million as of September 30, 2025, provide funding to the end of Q3 2027 excluding any income from potential milestonesPeer-reviewed papers covering groundbreaking results including clinical data on ACI-35...
Nasdaq GlobeNewswire
04/11/2025

Sky Labs Attracts Investment With Omron Subsidiary 'OMRON VENTURES'

In addition, it has also signed a Memorandum of Understanding (MoU) with OMRON Healthcare Co., Ltd.(Head Office: Muko, Kyoto, President & CEO: Ayumu Okada) a global blood pressure monitoring market leader, regarding strengthening its strategic partnership. In addition, it has also signed a Memorandum of Understanding (MoU) with OMRON Healthcare Co., Ltd.(Head Office: Muko,Kyoto, President & CEO:Ayumu Okada ) a global blood pressure monitoring market leader, regarding strengthening its...
PR Newswire
04/11/2025

Elastomeric Infusion Pumps Market worth $1.49 billion by 2030 - Exclusive Report…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=10422815 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=10422815 Elastomeric infusion pumps are advanced, non-electronic medical devices that enable controlled, continuous drug delivery in home care, hospice, and ambulatory settings. These devices are commonly used in the management of oncology, pain management, and palliative care, providing a safe, accurate, and portable...
PR Newswire
04/11/2025

Next-Generation Multiple Myeloma Therapies Market to Reach USD 37.07 Billion by…

Download PDF Brochure: https://www.datamintelligence.com/download-sample/next-generation-multiple-myeloma-therapies-market Download PDF Brochure:https://www.datamintelligence.com/download-sample/next-generation-multiple-myeloma-therapies-market Browse in-depth TOC on "Next-Generation Multiple Myeloma Therapies Market" 73 – Tables 67 – Figures 199 – Pages Beyond therapeutics, diagnostics are experiencing a paradigm shift. A multicenter trial usingwhole-body MRI (MY-RADS)...
PR Newswire
04/11/2025

Softgels Dietary Supplements Market to Surpass USD 358.6 Billion by 2032, Driven…

Growth Drivers: Preventive Health and Technological Advancements Growth Drivers: Preventive Health and Technological Advancements The global dietary supplement industry is being reshaped by measurable trends that directly influence softgel consumption patterns: Download PDF Brochure:https://www.datamintelligence.com/download-sample/softgels-dietary-supplements-market Browse in-depth TOC on "Softgels Dietary Supplements Market"70 – Tables 66 – Figures 195 – Pages ...
PR Newswire
04/11/2025

GHA Awards Top Honor to VitalLife: "Certified with Distinction" Recognizes…

"Receiving 'Certified with Distinction' from GHA is a testament to the dedication of our clinicians, care teams and partners to deliver world-class, evidence-driven care for international patients," said Asst.Prof.Dr. Polakit Teekakirikul, CEO of VitalLife Scientific Wellness Center. "Our mission is to combine scientific based wellness programs with a hospitality-minded patient experience. This recognition both validates our approach and reinforces our commitment to continuously…
PR Newswire
04/11/2025

24 million new wishes added in just one month to GoWish shows what we want under…

"Users of GoWish have started creating their Christmas wish lists earlier this year, giving us a clear picture of what's topping the lists - and what might be a good idea to put under the tree for loved ones this Christmas", says Casper Ravn-Sørensen, Chief Growth Officer at GoWish, noting that the GoWish-app on Nov 3 was the 2nd most downloaded on the US App Store. "Users of GoWish have started creating their Christmas wish lists earlier this year, giving us a clear picture of…
PR Newswire
04/11/2025

From Pandemic Innovation to Global Collaboration: Taiwan's TCM Shines at CPHI…

The Pavilion was also invited to appear on the CPHI Newsbeat Stage— the first time a Taiwanese exhibitor has ever been selected for this global media platform. During the session, it delivered a brief announcement on Taiwan's evidence-based TCM development, followed by an interview with Raman Sehgal, host of the Molecule to Market podcast, with around 10 media outlets in attendance. The exposure further elevated Taiwan's international visibility at the event. The Pavilion was also invited to...
PR Newswire
04/11/2025

Invitation to presentation of BioArctic's third quarter report for July -…

If you wish to participate via webcast, please use the link below. Via the webcast you will be able to ask written questions. If you wish to participate via webcast, please use the link below. Via the webcast you will be able to ask written questions. Webcast:https://bioarctic.events.inderes.com/q3-report-2025/register If you wish to participate via teleconference, please register on the link below. After registration you will be provided with phone numbers and a conference ID to...
PR Newswire
04/11/2025

NCCN Celebrates Expanding Access to Cancer Treatment in Africa at 2025 AORTIC…

The NCCN Global Program has been working with the American Cancer Society, the African Cancer Coalition, and other groups since 2017. That year, the organizations jointly announced the launch of NCCN Harmonized Guidelines™ for Sub-Saharan Africa driven by the leadership of the African Cancer Coalition. Those resources—based on the trusted NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) that cancer care providers worldwide rely on—used color-coding to represent both the optimal…
PR Newswire
04/11/2025

Elevaris Introduces CDMO Services, Procedural Needle Portfolio to EMEA

"Elevaris Medical Devices brought together two long-trusted companies with highly complementary capabilities," said Richard Zrebiec, CEO of Elevaris Medical Devices, "and we're thrilled to introduce these offerings on Europe's largest stage for medical device manufacturers. "Elevaris Medical Devices brought together two long-trusted companies with highly complementary capabilities," saidRichard Zrebiec, CEO of Elevaris Medical Devices, "and we're thrilled to…
PR Newswire
04/11/2025

Zelluna ASA: Disclosure of large shareholding

In accordance with the Norwegian Securities Trading Act Section 4-3, Inven2 AS ( “Inven2” ) hereby notifies that its ownership interest in Zelluna ASA (“Zelluna”) has fallen below the 10% threshold following the share capital increase in Zelluna through the private placement on November 3 rd2025. Previous shareholding : 10,79% New shareholding : 9,01% Total number of shares held: 2,207,034The reduction in ownership is due to dilution as result of the private placement. Inven2 has not...
Nasdaq GlobeNewswire
04/11/2025

Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley

COPENHAGEN, Denmark, November 4, 2025– Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 5.12% of the shares and voting rights in Bavarian Nordic A/S as of October 29, 2025.About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox...
Nasdaq GlobeNewswire
04/11/2025

Coloplast A/S - Annual Report 2024/25 & Remuneration Report 2024/25

Coloplast A/S - Annual Report 2024/25 & Remuneration Report 2024/25FY 2024/25 organic growth of 7% and EBIT margin 1of 28%. Reported revenue in DKK grew 3% to DKK 27,874 million.• Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice & Respiratory Care 9%, Wound & Tissue Repair 8% and Interventional Urology 2%. • EBIT 1,2was DKK 7,670 million, a 5% increase from last year. The EBIT margin 1,2was 28%, against 27% last year. • Adjusted 3net...
Nasdaq GlobeNewswire
04/11/2025
Altri  Comunicati